CIBC Asset Management Inc Has $52.45 Million Holdings in IQVIA Holdings Inc. $IQV

CIBC Asset Management Inc lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 232,701 shares of the medical research company’s stock after selling 4,667 shares during the period. CIBC Asset Management Inc owned about 0.14% of IQVIA worth $52,453,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in IQVIA by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock worth $4,429,426,000 after buying an additional 159,899 shares during the period. Geode Capital Management LLC raised its holdings in IQVIA by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock worth $982,272,000 after buying an additional 24,453 shares during the period. Alliancebernstein L.P. raised its holdings in IQVIA by 1.2% during the 3rd quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock worth $683,323,000 after buying an additional 41,643 shares during the period. Boston Partners acquired a new stake in IQVIA during the 3rd quarter worth about $676,698,000. Finally, Artisan Partners Limited Partnership increased its holdings in shares of IQVIA by 4.9% in the 3rd quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock valued at $652,246,000 after purchasing an additional 161,085 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on IQV shares. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and upped their target price for the company from $174.00 to $213.00 in a report on Monday, March 9th. Evercore reiterated an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a report on Wednesday, April 8th. Weiss Ratings downgraded IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Truist Financial dropped their target price on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a report on Thursday, February 19th. Finally, Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price on the stock in a report on Friday, March 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $224.13.

IQVIA Trading Up 0.8%

NYSE:IQV opened at $182.12 on Thursday. The stock’s 50 day moving average price is $171.35 and its 200 day moving average price is $195.26. IQVIA Holdings Inc. has a 52 week low of $143.00 and a 52 week high of $247.04. The company has a market capitalization of $30.40 billion, a P/E ratio of 22.57, a P/E/G ratio of 1.73 and a beta of 1.21. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter in the prior year, the company posted $2.70 earnings per share. The firm’s revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, research analysts forecast that IQVIA Holdings Inc. will post 11.58 EPS for the current fiscal year.

IQVIA declared that its board has approved a share repurchase program on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its stock is undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.